The Trep-AB clinical trial will test the efficacy of an investigational neuropenetrative
drug, Linezolid (LZD), compared to standard treatment, Benzathine penicillin G (BPG), for
early syphilis in humans. The overarching idea of the work proposed herein is to investigate
the use of LZD to treat syphilis, conducting a randomized controlled clinical trial to
evaluate this new indication of a known antibacterial agent. It is estimated to include 360
participants.
Phase:
Phase 3
Details
Lead Sponsor:
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia